The future of antiphospholipid antibody testing

Area of Science:

• Immunology
• Clinical Diagnostics
• Autoimmunity

Background:

• Antiphospholipid antibodies (aPL) are crucial for diagnosing antiphospholipid syndrome (APS).
• Existing assays for aPL detection have significant limitations, including lack of standardization and inability to predict clinical outcomes.
• The specific autoantibody populations responsible for APS manifestations and recurrence risk remain unclear with current methods.

Purpose of the Study:

• To highlight the limitations of current antiphospholipid antibody (aPL) assays in diagnosing and managing antiphospholipid syndrome (APS).
• To emphasize the urgent need for novel diagnostic assays that provide prognostic information for personalized APS patient care.
• To explore the potential of targeting β2-glycoprotein I (β2GPI) for developing improved assays based on recent physiological understanding.

Main Methods:

• Review of current diagnostic assays for antiphospholipid antibodies (aPL).
• Discussion of the limitations including standardization issues, unclear clinical relevance, and lack of prognostic value.
• Exploration of recent advancements in understanding β2-glycoprotein I (β2GPI) physiology.

Main Results:

• Current aPL assays lack standardization across laboratories.
• It is uncertain if current assays detect autoantibodies driving APS clinical manifestations.
• Existing assays do not predict the risk of APS recurrence.

Conclusions:

• There is a critical need for novel assays to improve antiphospholipid syndrome (APS) diagnosis and management.
• Understanding β2-glycoprotein I (β2GPI) physiology offers a pathway to develop assays with better prognostic capabilities.
• Improved assays could lead to more tailored treatment strategies for patients with APS.